Investment sentiment around
Insulet Corporation (NASDAQ:PODD) has been fluctuating with mixed perspectives from various asset management companies. Talking about the buys,
Teachers Retirement System of The State of Kentucky and
Plato Investment Management Ltdhas increased their stock positions while some other entities such as
Advisors Asset Management Inc. and
Public Employees Retirement Association of Colorado have reduced their holdings. Recently, there have been insider sales from
Director Timothy Scannell and
SVP & Chief Technology Officer Mark Field. The company has shown strong financials with robust Q4 2023 results and a Q1 2024 earnings top with
23% year-over-year revenue increase. Insulet's innovation in diabetes treatment was highlighted with the successful
Omnipod 5 system, now being launched in France and US, accepted well in type 2 diabetes studies, and receiving CE Mark approval for additional sensor compatibility. The company faces yet increasing competition in the insulin delivery systems market.
Insulet Corporation PODD News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Sun, 04 Aug 2024 15:14:38 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor 1
